Health Economics›Multiple myeloma›First-line therapy triplets

First-line therapy triplets

Multiple myeloma · 21 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 12 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Dara-Rd Variant #01	—	R 372 680	28d	61.9 mo	—	68	R 25 342 270 PFS proxy	4
KMP Variant #01	—	R 244 278	42d	22.3 mo	—	17	R 4 152 731 PFS proxy	1
KRd Variant #05	—	R 185 594	28d	34.6 mo	—	38	R 7 052 582 PFS proxy	2
KCD Variant #02	—	R 180 103	28d	—	—	—	—	—
KTD Variant #01	—	R 156 174	28d	—	—	—	—	—
MPT Variant #08	—	R 96 037	42d	21.2 mo	46.5 mo	16	R 1 536 595 PFS proxy	7
IRd Variant #01	—	R 65 250	28d	35.3 mo	—	39	R 2 544 736 PFS proxy	1
VTD Variant #10	—	R 46 769	42d	35.8 mo	—	26	R 1 215 998 PFS proxy	1
CTD Variant #02	—	R 42 203	28d	—	—	—	—	—
VTP Variant #01	—	R 33 545	42d	—	43.0 mo	—	—	1
TAD (Thalidomide) Variant #01	—	R 18 069	28d	—	—	—	—	—
PAD (Pegylated liposomal doxorubicin substituted) Variant #02	—	R 15 511	21d	—	—	—	—	—
VMP Variant #05	—	R 13 012	42d	17.3 mo	56.4 mo	13	R 169 162 PFS proxy	8
VDC Variant #04	—	R 10 611	35d	30.0 mo	—	27	R 286 501 PFS proxy	1
RVD Variant #01	—	R 10 486	28d	38.7 mo	—	43	R 450 885 PFS proxy	6
BBD Variant #01	—	R 8 280	28d	—	—	—	—	—
MPR N/A - secondary systemic drug	—	R 6 340	28d	24.0 mo	—	27	R 171 181 PFS proxy	6
Isa-Rd Variant #01 Partial	—	R 5 619	28d	—	—	—	—	—
CPR Variant #01	—	R 5 606	28d	20.0 mo	—	22	R 123 329 PFS proxy	2
CRd Variant #07	—	R 4 002	28d	—	—	—	—	—
PAD N/A - secondary systemic drug	—	R 0	28d	35.0 mo	—	39	R 0 PFS proxy	2

21 of 21 regimens shown